Astellas Pharma
AskBiography Logo   Latest News  Follow Us on Twitter  Follow Us on Google Buzz  Became Fan - Facebook  Subscribe to RSSRSS   Bookmark and Share

Astellas Pharma

Company nameAstellas Pharma Inc.
Company typePublic KK (Tyo - 4503)
IndustryPharmaceuticals
Founded2005 (from merger)
HeadquartersTokyo, Japan
Key peopleMasafumi Nogimori, President & CEO
Revenue(+) ¥ 972,586 million JPY (FY 2007)
Net income(+) ¥ 177,437 million JPY (FY 2007)
Employees13,900 (2007)

     Home | Company | Astellas Pharma



|} is a Japanese pharmaceutical company, formed on 1 April 2005 from the merger of

|} and

|}.

Astellas' franchise areas are urology, immunology (transplantation), dermatology, cardiology, and infectious disease. Priority areas for R&D are infectious diseases, diabetes, gastrointestinal diseases, oncology, and diseases of the central nervous system.

The company's headquarters are in Tokyo, with research centres in Tsukuba and Osaka. Clinical development is centred in Deerfield, Illinois and Leiderdorp, Netherlands. Combined revenues of the two pre-merger companies were $7.9 billion in 2004. Worldwide the company employs about 17,000 people.

Latest News : Astellas Pharma : Tweet this RSS

CORRECTED - CORRECTED-UPDATE 2-Astellas Q1 profit down, outlook slashed - Reuters Tweet this news
Reuters--TOKYO, Aug 2 (Reuters) - Japan's -Astellas Pharma- (4503.T) on Monday reported an 18.2 percent drop in first-quarter recurring profit amid ... - Date : Tue, 03 Aug 2010 02:21:19 GMT+00:00
Maxygen Reports Second Quarter 2010 Financial Results - MarketWatch (press release) Tweet this news
MarketWatch (press release)---...- a majority owned subsidiary, under its collaboration agreements with -Astellas Pharma- Inc., pursuant to which the parties are collaborating on the ... - Date : Wed, 04 Aug 2010 20:21:29 GMT+00:00
Japan's Astellas 1st-qtr FY 2011 profits plummet, hit by generic competition - The Pharma Letter Tweet this news
The Pharma Letter---Astellas Pharma-, Japan's second-largest drugmaker, reported a 5.5% drop in sales for the first quarter of its 2011 fiscal year, to 237.49 billion yen ($2.74 ... - Date : Wed, 04 Aug 2010 10:41:13 GMT+00:00
Four appointed to East St. Louis financial oversight panel - Belleville News Democrat Tweet this news
Belleville News Democrat--Lampkin is a senior regional sales manager for -Astellas Pharma- US. * Clarence Ellis Sr., of East St. Louis, a longtime community leader with experience as ... - Date : Wed, 04 Aug 2010 08:03:34 GMT+00:00
Maxygen Reports Second Quarter 2010 Financial Results - Earthtimes (press release) Tweet this news
Earthtimes (press release)---...- a majority owned subsidiary, under its collaboration agreements with -Astellas Pharma- Inc., pursuant to which the parties are collaborating on the ... - Date : Wed, 04 Aug 2010 20:29:59 GMT+00:00
Astellas completes $4B purchase of OSI Pharma - BusinessWeek Tweet this news
BusinessWeek--Japanese drugmaker -Astellas Pharma- Inc. on Wednesday announced that it has completed its $4 billion acquisition of OSI Pharmaceuticals Inc., a deal Astellas ... - Date : Thu, 10 Jun 2010 04:22:48 GMT+00:00
Astellas Announces Oral Presentation of SGLT2 Inhibitor Detailing Safety and ... - PR Newswire (press release) Tweet this news
PR Newswire (press release)---Astellas Pharma- Inc., located in Tokyo, Japan, is a pharmaceutical company dedicated to improving the health of people around the world through the ... - Date : Mon, 28 Jun 2010 12:02:34 GMT+00:00
Astellas, Teva Settle Patent Dispute In US - NIKKEI.com Tweet this news
NIKKEI.com--TOKYO (Nikkei)---Astellas Pharma- Inc. (4503) said Monday that it has reached a settlement in a US patent infringement lawsuit against Teva Pharmaceutical ... - Date : Mon, 28 Jun 2010 15:09:04 GMT+00:00
Merck heart rhythm drug endorsed by EU agency - Alibaba News Channel Tweet this news
Alibaba News Channel--Japan's -Astellas Pharma- holds North American rights to the intravenous formulation of vernakalant. Under terms of the agreement, Merck will pay Cardiome an ... - Date : Mon, 28 Jun 2010 03:13:20 GMT+00:00
Astellas Announces Successful Completion of Initial Tender Offer for Shares of ... - PR-USA.net (press release) Tweet this news
PR-USA.net (press release)---Astellas Pharma- Inc. announced today the completion of the initial tender offer for all outstanding shares of common stock in OSI Pharmaceuticals, Inc.. ... - Date : Mon, 07 Jun 2010 15:11:44 GMT+00:00

JP TOPIX 100 companies of Japan

Core 307&i * Astellas * Canon * Honda * JFE * JR East * JT * KDDI * KEPCO * Komatsu * Mitsubishi Corporation * Mitsubishi Estate * Mitsui & Co. * Mizuho * MUFG * Nintendo * Nippon Steel * Nissan * Nomura * NTT * NTT docomo * Panasonic * Shin-Etsu * Sony * Sumitomo Mitsui Financial * Takeda * TEPCO * Tokio Marine * Toshiba * Toyota
Large 70ÆON * AGC * Asahi Kasei * Bank of Yokohama * Bridgestone * Chubu Electric Power * Daiichi Sankyo * Daikin * Daiwa House * Daiwa Securities * Denso * DNP * Eisai * FANUC * Fujifilm * Fujitsu * Hitachi * Hoya * INPEX * Itochu * JR Central * JR West * Kao * Keyence * Kirin * Kobelco * Kubota * Kyocera * Kyushu Electric Power * Marubeni * Mitsubishi Chemical * Mitsubishi Electric * Mitsubishi Heavy Industries * Mitsui Fudosan * MOL * MSIG * Murata * NEC * Nidec * Nikon * Nippon Oil * Nitto Denko * ORIX * Resona * Ricoh * Rohm * Secom * Sekisui House * Sharp * Shiseido * SMC * SoftBank * Sompo Japan * Sumitomo Chemical * Sumitomo Corporation * Sumitomo Electric * Sumitomo Metal Mining * Sumitomo Metals * Sumitomo Realty * Sumitomo Trust * Suzuki * T&D * TDK * Tohoku Electric Power * Tokyo Electron * Tokyo Gas * Toppan * Toray * Yahoo! Japan * Yamada Denki



Privacy | Sitemap